iwCAR-T 2026: CARs targeting cell surface proteins

About this episode

A panel of experts discusses the advancements and challenges in CAR T-cell therapy for solid tumours.

In this roundtable discussion from iwCAR-T 2026, a panel of experts in cell therapy for solid tumours discuss the current state of CAR T-cell therapy beyond hematological malignancies. The panel explores key challenges including target selection, T-cell persistence, and the immunosuppressive tumour microenvironment, alongside emerging strategies such as armoured CARs, combination approaches with targeted therapies, and in vivo CAR T-cell generation. The discussion also addresses the importance of patient selection and earlier lines of therapy, and considers how academic–industry partnerships and evolving manufacturing technologies may shape the future of the field.

Topics covered

• CAR T-cell therapy
• solid tumours
• cell therapy
• tumour microenvironment
• patient selection
• academic-industry partnerships

Keywords

• CAR T-cell therapy
• solid tumours
• target selection
• T-cell persistence
• immunosuppressive microenvironment
• armoured CARs
• combination therapies
• patient selection

Mentioned in this episode

Organizations: VJOncology

Products: CAR T-cell therapy, armoured CARs, targeted therapies

More episodes of VJOncology Podcast

• Gastrointestinal cancer updates at ASCO 2026: RASolute 302, EMERALD-3, and more · June 12, 2026 · 16 min
• Highlights from ASCO 2026 · June 8, 2026 · 19 min
• Bladder Cancer Awareness Month: subtypes, diagnostics & breakthroughs · May 8, 2026 · 16 min
• Oncology highlights from AACR 2026 · May 1, 2026 · 18 min
• Beyond EGFR: navigating molecular targets and emerging therapies in advanced NSCLC · April 30, 2026 · 17 min
• Head and neck cancer awareness month: key trials and evolving treatment strategies · April 17, 2026 · 14 min